Herpes simplex virus type 2 (HSV-2) infects the barrier tissue lining the skin and mucosal tract and establishes lifelong infection. Some people experience frequent, painful lesions, while others remain asymptomatic. There is currently no cure or vaccine. HSV first replicates in mucosal epithelial cells, including keratinocytes, the predominant cell type in the outer layer of the skin. After initial rounds of replication, the viral progeny then travel through an innervating nerve network to infect nearby sensory neurons, where the virus often becomes latent, meaning it stops replicating but persists for life. Stress can trigger reactivation, causing a return of ulcerative lesions.
Tissue-resident memory T cells (TRMs) are critical for controlling HSV reactivation. They patrol sites of prior infection and release cytokines, small signaling proteins that coordinate early immune responses. One group of these cytokines, interferons (IFNs), establishes an antiviral state in nearby cells, stimulating the expression of antiviral interferon stimulated genes (ISGs) to restrict viral infection. Previous work showed interferon-γ (IFN-γ), is important for controlling HSV-2 infection. However, how epithelial cells differ in IFN-γ responsiveness to control reactivation, and how this differs between asymptomatic and symptomatic individuals was not understood.
In their new study, researchers from the Zhu and Corey labs collected keratinocytes and fibroblasts from skin biopsies of people with asymptomatic or recurrent ulcerative infection, to better understand cell-specific differences in IFN-γ responses. They treated the cells with various doses of IFN-γ and measured changes in ISG expression. Patient-derived primary keratinocytes were extremely sensitive to low levels of IFN-γ, responding to amounts far below those commonly used in earlier studies. Keratinocytes also responded more strongly than fibroblasts from the same donors, even though fibroblasts had higher baseline expression of many of these ISGs. The clearest effect was for CXCL10, a chemokine (a small, secreted protein that directs immune cell migration), which rose on average by 8,941-fold after treatment in keratinocytes compared to 410-fold in their fibroblast counterparts.
Keratinocytes from people with asymptomatic infection responded more strongly to very low amounts of IFN-γ than keratinocytes from people with recurrent lesions, producing far more CXCL10 and related chemokines. At the lowest dose tested, CXCL10 expression rose roughly 1,000-fold on average in asymptomatic donors versus about 40-fold in ulcerative donors. This was true for multiple chemokines, with asymptomatic donors producing more CXCL10 and CXCL11 protein. These differences faded at higher doses, suggesting heavier dosing in earlier studies masked these effects. Pretreatment with IFN-γ limited HSV replication equally among cells from ulcerative or asymptomatic individuals. This suggests the difference between asymptomatic and ulcerative disease may lie in more effective immune cell recruitment by these structural cells rather than direct viral control.
The authors suggest a model where small amounts of IFN-γ released by a few TRM cells could drive rapid chemokine production in keratinocytes, recruiting and positioning T cells to contain reactivated HSV before ulceration develops. Dr. Zhu notes that these findings, “expand the current view of antiviral immunity by showing that structural cells are not merely passive targets of infection,” Dr. Zhu says that future work in the lab aims to focus on, “how structural cells influence the establishment, maintenance, and function of TRM cells, and how this interaction affects susceptibility or resistance to recurrent HSV infection.”
This research was supported by the National Institutes of Health.
Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium Member Dr. Larry Corey (Fred Hutch) contributed to this research.
Zimenko A, Hayman I, Fong Y, Monroe LD, Mills MG, Greninger A, Johnston C, Corey L, Zhu J. 2026. Epithelial interferon-γ responsiveness shapes chemokine induction and clinical outcomes in herpes simplex virus infection. PLOS Pathogens. DOI: 10.1371/journal.ppat.1014612.